Skip to main content

ACROBiosystems establishes presence in the Basel Area

| News

ACROBiosystems establishes presence in the Basel Area


ACROBiosystems AG, who operates in the US and in Asia, has selected the Basel Area for its first European location. From here, the biopharmaceutical firm headquartered in Beijing plans to expand its research and commercial activities in Europe.

ACROBiosystems about the Basel Area

ACROBiosystems, which is headquartered in Beijing, is to establish a presence at the Allschwil site of the Switzerland Innovation Park Basel Area. This is the biopharmaceutical firm’s first European subsidiary, while it already operates a site in Newark in the US State of Delaware (read more about starting a business in Switzerland). From the Basel Area, ACROBiosystems intends to expand its research and commercial activities across Europe, according to a statement. Both, the investment and innovation promotion agency Basel Area Business & Innovation and the foundation Switzerland Innovation, which brings innovative companies into contact with scientific institutions, supported ACROBiosystems in establishing its business in the area. “We welcome ACROBiosystems as promising contributor to our vibrant life sciences community at the Switzerland Innovation Park Basel Area in Allschwil”, comments Karin Crisanto, Head Innovation Space and Infrastructure at Basel Area Business & Innovation. “With its focus on collaboration with local customers and partners the company is a good fit for us.”

Basel Area as a valuable base

ACROBiosystems manufactures proteins, antibodies and other reagents for biopharmaceutical research. According to information from the company itself, by opening a new subsidiary, the aim is “to accelerate the growth of the company with our first active presence in Europe. The company supports academic and industrial clients working on target therapeutics, vaccines and diagnostics in all phases of product development.” As CEO Mike Chen explains, ACROBiosystems is keen to “foster better relationships with renowned universities, research institutions and hospitals in Switzerland” with the ultimate aim of supporting “new product development to better understand and serve the biomedical field”.

The new location in the Basel Area is “exciting for us as it offers a valuable base for sales and marketing, better geographic coverage of our customers and collaborators and provides a foundation for our future plans of developing a facility for manufacturing, research and development to grow from”. Chen explains further in the statement.

Learn what it’s like to work in Switzerland, what permits you need as a foreign worker and how to find work here. Check out our working in Switzerland page for more info.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More